Neuland Laboratories Ltd (NEULANDLAB) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 229993, "name": "Neuland Labs.", "stock_name": "Neuland Labs.", "full_name": "Neuland Laboratories Ltd", "name_url": "stocks-analysis/neuland-labs", "exchange": 0, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "17,179.55", "chg": 111.65, "chgp": "0.65%", "dir": 1, "prev_price": "17,067.90", "mcapval": "21,849.00 Cr", "mcap": "Small Cap", "scripcode": 524558, "symbol": "NEULANDLAB", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "India SENSEX", "isin": "INE794A01010", "curr_date": "Jun 01", "curr_time": "", "bse_nse_vol": "84.39 k", "exc_status": "Active", "traded_date": "Jun 01, 2026", "traded_date_str": "2026 06 01", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/neuland-labs-229993-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Golden Cross Confirmed: Do Neuland Laboratories Ltd's Other Technical Indicators Agree?", "link": "https://www.marketsmojo.com/news/stocks-in-action/neuland-laboratories-ltd-forms-golden-cross-signalling-potential-bullish-breakout-4027106", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/NeulandLaborato_goldencross_4027106.png", "date": "2026-06-01 18:00:19", "description": "The 50-day moving average has crossed above the 200-day moving average for Neuland Laboratories Ltd, signalling a golden cross on 1 Jun 2026. While this technical event often suggests a shift towards bullish momentum, the broader technical and fundamental context presents a nuanced picture that merits closer examination." }, { "title": "Neuland Laboratories Gains 2.61%: Technical Shift and Valuation Concerns Shape the Week", "link": "https://www.marketsmojo.com/news/stocks-in-action/neuland-laboratories-gains-261-technical-shift-and-valuation-concerns-shape-the-week-4024561", "imagepath": "", "date": "2026-05-31 13:00:05", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>May 25:</strong> Stock opens at Rs.16,742.45, Sensex gains 1.23%</p>\n <p><strong>May 26:</strong> Stock surges 1.88% to Rs.17,056.90 despite Sensex decline</p>\n <p><strong>May 27:</strong> Downgrade to Hold announced amid mixed technical and valuation signals</p>\n <p><strong>May 29:</strong> Stock closes strong at Rs.17,067.90, up 1.84% on the day</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.16,634.05</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div>..." }, { "title": "Neuland Laboratories Downgraded to Hold Amid Mixed Technical Signals and Valuation Concerns", "link": "https://www.marketsmojo.com/news/stock-recommendation/neuland-laboratories-downgraded-to-hold-amid-mixed-technical-signals-and-valuation-concerns-4015839", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/NeulandLaborato_mojoScore_4015839.png", "date": "2026-05-27 08:05:16", "description": "Neuland Laboratories Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 26 May 2026. This revision reflects a nuanced assessment across four critical parameters: Quality, Valuation, Financial Trend, and Technicals. Despite robust financial performance and strong returns, evolving technical indicators and valuation metrics have prompted a more cautious stance from analysts." }, { "title": "Neuland Laboratories Ltd Technical Momentum Shifts Amid Mixed Indicator Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/neuland-laboratories-ltd-technical-momentum-shifts-amid-mixed-indicator-signals-4015570", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/NeulandLaborato_technicaldot_4015570.png", "date": "2026-05-27 08:00:51", "description": "Neuland Laboratories Ltd has experienced a notable shift in its technical momentum, transitioning from a mildly bullish stance to a more sideways trend. Despite a 1.88% gain on 27 May 2026, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators, prompting a downgrade in its Mojo Grade from Buy to Hold." }, { "title": "Neuland Laboratories Falls 6.35%: 4 Key Factors Driving the Weekly Decline", "link": "https://www.marketsmojo.com/news/stocks-in-action/neuland-laboratories-falls-635-4-key-factors-driving-the-weekly-decline-3995541", "imagepath": "", "date": "2026-05-17 13:00:04", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>11 May:</strong> Stock opens at Rs.17,548.30, declines 0.82%</p>\n <p><strong>12 May:</strong> Sharp drop of 3.12% amid low volume</p>\n <p><strong>13 May:</strong> Strong gap up and record quarterly results announced</p>\n <p><strong>14 May:</strong> Partial recovery with 1.51% gain</p>\n <p><strong>15 May:</strong> Week closes at Rs.16,570.70, down 0.79%</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.17,548.30</div></div>\n <div class=\"stat-item\"><div class=\"stat..." }, { "title": "Neuland Laboratories Ltd is Rated Buy", "link": "https://www.marketsmojo.com/news/stock-recommendation/neuland-laboratories-ltd-is-rated-buy-3995475", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/NeulandLaborato_mojoScore_3995475.png", "date": "2026-05-17 10:10:03", "description": "Neuland Laboratories Ltd is rated Buy by MarketsMOJO, with this rating last updated on 12 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 17 May 2026, providing investors with the latest insights into the company’s performance and outlook." }, { "title": "Are Neuland Laboratories Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-neuland-laboratories-ltd-latest-results-good-or-bad-3989938", "imagepath": "", "date": "2026-05-13 19:17:02", "description": "Neuland Laboratories Ltd has reported its Q4 FY26 financial results, showcasing significant quarter-on-quarter growth. The company achieved net sales of ₹776.25 crores, reflecting a 76.54% increase from the previous quarter, alongside a remarkable net profit of ₹212.67 crores, which represents a 424.21% rise compared to Q3 FY26. This quarter's performance marks a notable turnaround from the preceding quarter, driven by robust revenue growth and substantial improvements in operating margins, which reached 39.59%, the highest in at least seven quarters.\n\nHowever, when viewed in the context of the full fiscal year FY25, the overall performance presents a more complex picture. For the year, Neuland Laboratories reported a decline in revenues of 5.3% to ₹1,476.00 crores and a net profit decrease of 13.33% to ₹260.00 crores compared to FY24. This divergence between the strong quarterly results and the annual perf..." }, { "title": "Neuland Laboratories Q4 FY26: Stellar Quarter Masks Valuation Concerns", "link": "https://www.marketsmojo.com/news/result-analysis/neuland-laboratories-q4-fy26-stellar-quarter-masks-valuation-concerns-3989574", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/NeulandLaborato_quaterlyResult_3989574.png", "date": "2026-05-13 10:01:41", "description": "Neuland Laboratories Ltd., a Hyderabad-based pharmaceutical manufacturer specialising in bulk drugs, has delivered an exceptional fourth quarter for FY26, posting a net profit of ₹212.67 crores—a staggering 424.21% surge quarter-on-quarter and 664.72% year-on-year. The ₹21,766.42-crore market cap company saw revenues soar to ₹776.25 crores in Q4 FY26, marking a 76.54% sequential jump and 136.40% annual growth. However, the stock's muted response—down 0.21% to ₹16,965.40 following the results—suggests investors are grappling with the company's elevated valuation multiples, including a price-to-earnings ratio of 123 times trailing earnings." }, { "title": "Neuland Laboratories Ltd Sees Robust Trading Activity Amid Sector Outperformance", "link": "https://www.marketsmojo.com/news/stocks-in-action/neuland-laboratories-ltd-sees-robust-trading-activity-amid-sector-outperformance-3989076", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/NeulandLaborato_most_active_equities_by_value_3989076.png", "date": "2026-05-13 10:00:07", "description": "Neuland Laboratories Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has emerged as one of the most actively traded stocks by value on 13 May 2026. The stock demonstrated robust investor interest, marked by a significant uptick in traded volume and value, alongside a notable upgrade in its Mojo Grade to ‘Buy’ from ‘Hold’ just days earlier." } ], "total": 771, "sid": "229993", "stock_news_url": "https://www.marketsmojo.com/news/neuland-laboratories-229993" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation", "datetime": "22-May-2026", "details": "Intimation about Schedule of Analyst / Institutional Investor Meeting on May 28 2026", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript", "datetime": "16-May-2026", "details": "Transcript of the Earnings Call conducted on May 12 2026", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "15-May-2026", "details": "Copy of Newspaper Publication", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Neuland Laboratories Ltd has declared <strong>120%</strong> dividend, ex-date: 18 Jul 25", "dt": "2025-07-18", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "", "data": [ { "txt": "Neuland Laboratories Ltd has announced <strong>4:25</strong> rights issue, ex-date: 13 Aug 14", "dt": "2014-08-13", "middle_text": "Rights Issue" } ] } ] }

Key Events This Week

11 May: Stock opens at Rs.17,548.30, declines 0.82%

12 May: Sharp drop of 3.12% amid low volume

13 May: Strong gap up and record quarterly results announced

14 May: Partial recovery with 1.51% gain

15 May: Week closes at Rs.16,570.70, down 0.79%

Week Open

Rs.17,548.30

Read full news article

Neuland Laboratories Ltd is Rated Buy

2026-05-17 10:10:03

Neuland Laboratories Ltd is rated Buy by MarketsMOJO, with this rating last updated on 12 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 17 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Are Neuland Laboratories Ltd latest results good or bad?

2026-05-13 19:17:02

Neuland Laboratories Ltd has reported its Q4 FY26 financial results, showcasing significant quarter-on-quarter growth. The company achieved net sales of ₹776.25 crores, reflecting a 76.54% increase from the previous quarter, alongside a remarkable net profit of ₹212.67 crores, which represents a 424.21% rise compared to Q3 FY26. This quarter's performance marks a notable turnaround from the preceding quarter, driven by robust revenue growth and substantial improvements in operating margins, which reached 39.59%, the highest in at least seven quarters. However, when viewed in the context of the full fiscal year FY25, the overall performance presents a more complex picture. For the year, Neuland Laboratories reported a decline in revenues of 5.3% to ₹1,476.00 crores and a net profit decrease of 13.33% to ₹260.00 crores compared to FY24. This divergence between the strong quarterly results and the annual perf...

Read full news article

Neuland Laboratories Q4 FY26: Stellar Quarter Masks Valuation Concerns

2026-05-13 10:01:41

Neuland Laboratories Ltd., a Hyderabad-based pharmaceutical manufacturer specialising in bulk drugs, has delivered an exceptional fourth quarter for FY26, posting a net profit of ₹212.67 crores—a staggering 424.21% surge quarter-on-quarter and 664.72% year-on-year. The ₹21,766.42-crore market cap company saw revenues soar to ₹776.25 crores in Q4 FY26, marking a 76.54% sequential jump and 136.40% annual growth. However, the stock's muted response—down 0.21% to ₹16,965.40 following the results—suggests investors are grappling with the company's elevated valuation multiples, including a price-to-earnings ratio of 123 times trailing earnings.

Read full news article

Neuland Laboratories Ltd Sees Robust Trading Activity Amid Sector Outperformance

2026-05-13 10:00:07

Neuland Laboratories Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has emerged as one of the most actively traded stocks by value on 13 May 2026. The stock demonstrated robust investor interest, marked by a significant uptick in traded volume and value, alongside a notable upgrade in its Mojo Grade to ‘Buy’ from ‘Hold’ just days earlier.

Read full news article